On Friday, Inozyme Pharma Inc (NASDAQ: INZY) opened lower -7.49% from the last session, before settling in for the closing price of $0.99. Price fluctuations for INZY have ranged from $0.91 to $7.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 12.96% at the time writing. With a float of $43.56 million, this company’s outstanding shares have now reached $64.24 million.
The firm has a total of 67 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Inozyme Pharma Inc (INZY) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Inozyme Pharma Inc is 32.20%, while institutional ownership is 59.13%. The most recent insider transaction that took place on Apr 02 ’24, was worth 52,210. In this transaction CEO of this company sold 7,523 shares at a rate of $6.94, taking the stock ownership to the 20,665 shares.
Inozyme Pharma Inc (INZY) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 12.96% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.09% during the next five years compared to -13.98% drop over the previous five years of trading.
Inozyme Pharma Inc (NASDAQ: INZY) Trading Performance Indicators
Check out the current performance indicators for Inozyme Pharma Inc (INZY). In the past quarter, the stock posted a quick ratio of 3.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.26 in one year’s time.
Technical Analysis of Inozyme Pharma Inc (INZY)
Analysing the last 5-days average volume posted by the [Inozyme Pharma Inc, INZY], we can find that recorded value of 0.42 million was lower than the volume posted last year of 0.72 million. As of the previous 9 days, the stock’s Stochastic %D was 34.43%. Additionally, its Average True Range was 0.09.
During the past 100 days, Inozyme Pharma Inc’s (INZY) raw stochastic average was set at 0.27%, which indicates a significant decrease from 5.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.99% in the past 14 days, which was lower than the 91.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2243, while its 200-day Moving Average is $3.5864. Now, the first resistance to watch is $0.9934. This is followed by the second major resistance level at $1.0666. The third major resistance level sits at $1.1032. If the price goes on to break the first support level at $0.8836, it is likely to go to the next support level at $0.8470. Should the price break the second support level, the third support level stands at $0.7738.
Inozyme Pharma Inc (NASDAQ: INZY) Key Stats
There are currently 64,240K shares outstanding in the company with a market cap of 59.11 million. Presently, the company’s annual sales total 0 K according to its annual income of -102,020 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -27,070 K.
